PAs and malpractice

CASE STUDY EXAMINES YOUR LITIGATION RISKS-AND THE FINDINGS MAY SURPRISE YOU

[By MATT LEDGES, MD, MS, PA; MICHAEL VICTOROFF, MD; and ADIT A. GINDE, MD, MPH]



laims and suits against physician assistants (PAs) and their supervising physicians are rare, and the outcomes usually are favorable for the defense. Some risks remain, however, and understanding agency law, liability, and the elements necessary for malpractice claims may give you a better vantage point in preventing lawsuits or winning them.

The PA profession has grown tremendously since its birth in the 1960s. Today, PAs are licensed in all 50 states and practice in most specialties and settings. The profession's popularity also is evident in an increasing number of PA schools, numerous independent rankings and growth projections, and recent global expansion.^{1,2,3}

Yet controversy remains regarding how PAs' malpractice litigation risk compares with that of physicians and to what extent doctors' risk of malpractice litigation is affected by supervising PAs. The dependent practice model remains at the core of the PA profession. It also fuels much of this debate, however.

LEGAL FRAMEWORK

The nature of a dependent practice unites PAs and physicians not only in individual patient care but also in any litigation that may develop as a result. The legal principle of agency is the basis of the PA- doctor relationship and underlies most states' statutes governing PA practice. Generally, agency law holds a supervising physician liable: 1) for his or her own negligent acts (direct liability); or 2) for the negligent acts of a subordinate PA (vicarious liability).⁴

Negligence claims are generally required to have four basic elements:

- The provider owed a duty to care.
- The provider breached that duty.
- The breach proximately caused an injury.
- The injury resulted in compensable legal damages.

In practice, both direct and vicarious liability may be alleged in a single case.

DIRECT LIABILITY

A PA acts with authority if the supervising doctor approves his or her conduct. In such cases, if the PA breaches his or her duty to the patient, the physician may be held directly liable. The doctor also may be held directly liable if he or she is negligent in selecting, supervising, or otherwise controlling the PA.

Negligent selection is a type of direct liability claim in which the physician can be liable for hiring a PA if the doctor knew or should have known the PA had some dangerous propensity. Here, the plaintiff must prove that the act of hiring the PA proximately caused injury and that the physician would have discovered the PA's propensities with reasonable diligence.

Negligent supervision is another type of direct liability claim; the acts of the doctor (and not necessarily those of the PA) are at issue. State statutes codify supervision requirements and, by extension, what constitutes negligent supervision. Statutes vary by state, but most address issues related to physician presence, acceptable PA-doctor ratios, and chart review obligations.⁵

Dynamic elements of PA practice such as clinical setting, level of experience, and employment duration may affect these requirements. Additionally, some states differentiate between primary and secondary supervisory relationships, adding to the complexity of what constitutes diligent supervision.

VICARIOUS LIABILITY

Agency law provides that a physician also may be held vicariously liable for negligent acts by a PA. *Respondeat superior*, Latin for "let the master answer," is

34 MEDICAL ECONOMICS October 10, 2011

MedicalEconomics.com



Characteristics

Physician assistants

Physicians

Male

Female

Rates of claims and suits against Colorado physician assistants compared with physicians, by year and gender

Claims/suits per 1.000 provider-

5.8

38.2

P value

< 0.001

Provider

5,204

21,393

the primary vehicle used to assert this type of liability. This principle provides that an employer is subject to liability for torts—civil wrongs—committed by employees acting within the scope of their employment.

The PA's status as employee or independent contractor is irrelevant as long as the patient reasonably believes the PA has authority to act on the doctor's behalf. *Respondeat superior* claims differ from negligent selection and negligent supervision claims in that the physician may be held solely liable for the negligent acts of the PA. In fact, under this principle, the supervising doctor may not have been present or even aware of the patient encounter.

These legal principles fuel competing theories comparing PAs and physicians. Some suggest that because PA school is shorter in duration than medical school and residency, PAs inherently have more litigation risk. This theory seems to rest on an assumption that shorter formal education translates to more errors of cognition and judgment and, therefore, more litigation risk.

In contrast, some suggest that PAs carry less litigation risk than their doctor counterparts, for two primary reasons. First, PAs commonly treat patients with less acute conditions and leave more complicated cases to physicians. This argument assumes that patients with lower acuity complaints are less likely to suffer harm and are less litigious.

The second argument is that two heads are better than one. The success of the pilot/co-pilot model is based on the fact that although two people both may make mistakes, it is unlikely they will each make the same mistake. The odds that the doctor and PA will make identical mistakes at the same time should be lower for the same reason. This argument contends that a culture of collaboration reduces injury—a critical tenet of risk management.

So which theory is correct? Are PAs involved in more or less malpractice litigation than physicians? Does intensity of doctor supervision affect the outcome of claims and suits?

As with the practice of medicine itself, the devil is in the details. Complexities of individual cases, heterogeneity of claims analyses, varying state statutes, and malpractice environments have limited discussion in the literature to case reports. Although such reports illustrate legal concepts or offer cautionary tales, they do not provide the necessary context to accurately gauge PA malpractice litigation risk.

PHYSICIANS SUED MORE OFTEN

We conducted the largest case series of PA claims to date, to analyze PA and physician malpractice litigation risk. Our primary aim was to determine the

October 10, 2011 MEDICAL ECONOMICS 35

Provider type-yea Physician assistants 0.006 2002-2004 2,176 9.2 2005-2007 3,028 3.3 Physicians 0.68 10.991 2002-2004 37.7 2005-2007 10,402 38.8 Provider type-ger 0.12 Physician assistants 1.889 7.9 Male Female 3,315 4.5 < 0.001 Physicians

41.1

30.2

rate of claims and suits brought against PAs versus doctors. Our secondary aims were to evaluate how intensity of supervision may factor into the outcome of the case, and to determine whether any other factors were more associated with cases that resulted in a settlement versus cases that were dismissed or otherwise not pursued.

15,730

5.663

To quantify PA and physician malpractice litigation risk, we performed a structured chart review of all claims and suits brought against Colorado-licensed PAs from January 1, 2002, to December 31, 2009. We limited our data collection to PAs and doctors who were insured by COPIC.

COPIC insures about three-fourths of physicians and two-thirds of PAs in the Colorado private market, making it the largest private professional liability carrier in the state. We used COPIC's definition of a claim: "Any demand for damages, arising from professional activity or circumstances, brought by a patient or patient representative, indicating the possibility of legal action."

With approval from the Colorado Multiple Institutional Review Board (COMIRB), we reviewed claim summaries, medical records, depositions, and other legal documents. We recorded data using a standardized data collection form. We identified a total of 34 claims and suits against Colorado-licensed PAs over an 8-year period, 32 of which were no longer active at the time of our analysis. Because Colorado statutes require that claims and suits be brought within 2 years from the time harm was first recognized, we limited our risk calculations and analysis of temporal trends

MedicalEconomics.com

Unfiled Notes Page 2

to the first 6 years of our 8-year study to account for much of this reporting lag.

Overall, PAs experienced 5.8 claims and suits per 1.000 provider years, whereas the doctors' rate was nearly seven times higher at 38.2 (see Table 1). Between 2002 and 2007, the rate of claims and suits against PAs dropped by nearly two-thirds, wheras the rate against physicians increased marginally.

Gender appeared to play a significant role in the rate of claims and suits against both PAs and doctors. Female providers experienced a considerably lower rate of claims and suits compared to their male counterparts.

Table 2 summarizes the clinical characteristics of the 34 claims and suits brought against PAs. A majority of cases involved primary care and emergency medicine/urgent care, each accounting for 14 cases (41%). Over one-half of the cases occurred in an outpatient setting.

Seven of the 34 cases began as claims but did not progress to lawsuits, whereas the remaining 27 did. Twenty cases (59%) were dismissed or otherwise not pursued, 11 (32%) settled, and two remained open (6%). Only one case went to trial and was successfully defended.

The most common presenting complaints involved the musculoskeletal, gastrointestinal, and neurologic systems, corresponding to 44%, 21%, and 15% of the cases, respectively. The most common patient outcomes were either a complication or worsening of the problem (32%), and death (21%). We found no injury alleged in two of the 34 cases.

The three categories of supervision were spread nearly equally: both the PA and physician examined the patient in 12 cases (35%), the doctor discussed the patient with the PA but did not examine the patient in nine cases (26%), and the *Continued on page 41*


TABLE 2

Characteristics of claims and suits brought against Colorado physician assistants, 2002 to 2009

ettled/Went o trialN=14
6 (50%)
7 (58%)
3 (25%)
2 (17%)
3 (25%)
6 (50%)
3 (25%)
8 (2-15)
5 (42%)
3 (25%)
4 (33%)
39 (0-82)
6 (50%)
0 (00 m)
3 (25%)
3 (25%)
2 (17%)
4 (33%)
4 (55 M)
4 (33%)
6 (50%)
2 (17%)
0 (0%)
4 (33%)
5 (42%)
1 (8%)
2 (17%)
1 (8%)
(92%)
12 (100%)
(100.0)
NA
(32%)
1 (3%)
NA NA
100K (\$13K to \$925K)
200K (\$159K to \$390K
(e.oon to eosidi
1K (\$53K to \$428K)
79K (\$30K to \$351K)

36 MEDICAL ECONOMICS October 10, 2011

MedicalEconomics.com




Indication and Usage

GRALISE[™] is indicated for the management of postherpetic neuralgia (PHN). GRALISE is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration.

Important Safety Information

GRALISE is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.

Please see Brief Summary of Prescribing Information. For full Prescribing Information and Medication Guide, please visit www.GRALISE.com.



with PHN the full day

with **NEW** once-daily GRALISE

Reduce the burdens of postherpetic neuralgia (PHN). **NEW** GRALISE offers **24-hour pain control**, **once-daily oral dosing, favorable tolerability**, and **effective 2-week titration.**^{1,2}

Effective 24-hour pain control¹

Significant and lasting improvement in pain scores in clinical trials.

Once-daily oral dosing with the evening meal^{1,2}

Patented polymer technology allows for peak plasma levels during the night and low rates of side effects.

Favorable tolerability profile^{1,2}

There was a reported incidence of dizziness (10.9% vs 2.2% placebo), somnolence (4.5% vs 2.7% placebo), and peripheral edema (3.9% vs 0.3% placebo) at 1800 mg once daily.

Reach an effective dose in 2 weeks1

Titration to an 1800 mg dose in 2 weeks.

Indication and Usage

GRALISE™ is indicated for the management of postherpetic neuralgia (PHN). GRALISE is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration.

Important Safety Information

GRALISE is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.

The most common adverse reaction to GRALISE (≥5% and twice placebo) is dizziness.

Across all GRALISE clinical trials the other most common adverse reactions (>2% vs placebo) are somnolence, headache, peripheral edema, diarrhea, dry mouth, and nasopharyngitis. The types and incidence of adverse events were similar across age groups except for peripheral edema, which tended to increase in incidence with age.

Antiepileptic drugs (AEDs) including gabapentin, the active ingredient in GRALISE, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.

Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Please see Brief Summary of Prescribing Information on next page. For full Prescribing Information and Medication Guide, please visit www.GRALISE.com.

References: 1. GRALISE [prescribing information]. Menlo Park, CA: Depomed Inc.; April 2011. 2. Data on file. Depomed Inc.



GRALISE™ (gabapentin) tablets

BRIEF SUMMARY: For full prescribing information, see package insert.

GRAUSE is indicated for the management of Posthemetic Narraigia PHN, GRAUSE is not interchange-able with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration. INDICATIONS AND USAGE

DOSAGE AND ADMINISTRATION

- DOSAGE AND ADMINISTRATION Positherpetic normarigia Tirtel GRAISE to an 1600 mg dose taken orally once daily with the evening meal. GRAISE tablets should be swalawee while. Do not spit, cruch, or chew the tablets. If GRAISE dose is reduced, discontinued, or substituted with an atomative medication, this should be done graduatily aver a minimum of me week or longer at the discretion of the proschedy. Renal impairment: Dose should be adjusted in patients with reduced renal function. GRAISE should not be used in patients with CPC less than 30 or in patients on themodaysis. In adults with postherpetic neuralgia, GRAISE therapy should be initiated and tirated as follows:

Table 1 GRALISE Recommended Titration Schedule

	Day 1	Day 2	Days 3-6	Days 7-10	Days 11-14	Day 15
Daily dose	300 mg	600 mg	900 mg	1200 mg	1500 mg	1800 mg

CONTRAINDICATIONS GRAUSE is contraindicated in patients with demonstrated hypersensitivity to the drug or its ingredients.

Table 2 GRALISE Dosage Based on Renal Function

Once-daily dosing	
Creatinine clearance (mL/min)	GRALISE dose (once daily with evening meal)
≥60	1800 mg
30-60	600 mg to 1800 mg
	ODALLOF should not be administrated

Patients receiving hemodialysis GRALISE should not be administered GRALISE should not be administered

Precision to every intercharges to every a subset of a model of a solution to the administration WANNINGS AND PRECAUTIONS GRAUSE is not interchargeship with other galagentin products because of differing pharmacokinetic profiles that affect the frequency of administration. The safety and effoctiveness of GRAUSE profiles with galagent has not been studied. Subsidial Belatware and Ideation Antiperpixels drugs (ADD), including galagentin, the active ingredient in GRAUSE, increase the risk of suicidal thoughts or behavior inpatients taking these drugs for any indication. Patients traded with any ADD for any indication should be monitored for the energience or worsening of depression, suicidal thoughts or behavior, and/or any unusual charges in mood or behavior.

Table 3 Risk by Indication for Antiepileptic Drugs (including gabapentin, the active ingredient

in Gralise) in the Pooled Analysis						
Indication	Epilepsy	Psychiatric	Other	Total		
Placebo patients with events per 1000 patients	1.0	5.7	1.0	2.4		
Drug patients with events per 1000 patients Relative risk: incidence of events in	3.4	8.5	1.8	4.3		
drug patients/incidence in placebo patients Risk difference: additional drug patients	3.5	1.5	1.9	1.8		
with avante par 1000 patients	2.4	20	0.0	10		

The relative about a top particles 2.4 2.9 0.9 1.9 The relative risk for available thoughts or behavior was higher in chical trials for aplicably than in clinical trials for paychietric or able candidot haughts or behavior was higher in chical trials for aplicably than in clinical trials for paychietric or able candidot haughts or behavior was higher in chical trials for aplicably and paycharis indications. Aryone cansidering prescribing (FALSE must balance the risk of suicidal fung), the about entits (Barrouse verse minimal for the episoge and paycharis the risk of uncertained liness, Episoya and many other indications can argue and exact components in GRAISE) are prescribed are themselves associated with motibility and intraily and an interess of risk of basicable that the component in GRAISE) are prescribed are themselves associated with motibility and intraily and an the liness being barlies that are ADDs (basic hange) and the lines being barlies that there are appress of the energence of these symptoms in any given patient may be related to be liness being barlies that there is the prescribent of the prescribent

humans or an the varianing a recurrence of previously diagnosed turnors is unknown. **AUMPERS ERACTIONS Clinical Traine Expansions** Because clinical traits are canducted undra videly varying conditions, underse reaction rates between of the cinical traits of a dug cannot be directly competed for date in the clinical traits of arother dug and may not reflect the rates disorved in practice. A total of 33D patients with neuropathic pair associated with postherptici neuropaties have received GRAEE at doss to pit 10 Boom g day during plaucho-centrated cinical studes. In clinical traits in patients with postherptic neuropaties. Or All the diverse reactions, In the GRAIES traitment project. The most common reason for discontinuation due to adverse reactions, adverses reactions were either "mild" or "moderate". Table 4 lists al adverse reactions, repartless of causally, group for which the incidence was groater Tam. In the gRAIES for adverse the reactional the GRAIES group for which the incidence was groater tam in the placebo group.

Table 4 Treatment-Emergent Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Postherpetic Neuralgia (Events in at Least 1% of all GRALISE-Treated Patients and More Frequent Than in the Placebo Group) %

Body system—preferred term	GRALISE N=359, %	Placebo N=364,	
Ear and Labyrinth Disorders			
Vertigo	1.4	0.5	
Gastrointestinal Disorders			
Diamhea	3.3	2.7	
Dry mouth	2.8	1.4	
Constipation	1.4	0.3	
Dyspepsia	1.4	0.8	
General Disorders			
Peripheral edema	3.9	0.3	
Pain	1.1	0.5	
Infections and Infestations			
Nasopharyngitis	2.5	2.2	
Urinary tract infection	1.7	0.5	
Investigations			
Weight increased	1.9	0.5	

Musculoskeletal and Conn Tissue Disorders Pain in extremity 1.9 1.7 0.5 1.1 Back pain Back pain Iervous System Dis Dizziness Somnolence 10.9 4.5 4.2 2.2 2.7 4.1 eadache Letharcy 0.3

Leftnergy 1.1 u.s. In addition to the adverse reactions reported in Table 4 above, the following adverse reactions with an uncertain reactionship to GRAUSE were reported during the clinical development for the treatment of postepetic neuragia. Events in more than 1% of patients but equally or more frequently in the GRAUSE-reated patients than in the placebo graph produced blood pressure recrease. critical clinical development for the treatment of postepetic neuragia. Interdition, prim seeling, memary implainment, nauce, protuntion, presize, radi, seasonal allergy, and topper registrary information. RestamArding and Other Experimence with other Formulations of Galapartini in addition to be adverse experiences reported form; clinical lessing of palavoritin, the dialognatin lines above there protocols and data are insufficient to support an estimate of their incidence or to establish causation. The stated above and data are insufficient to support an estimate of their incidence or to establish outsion. The state events following the admip discussion of palabove threads, Steenets-Jafrinon and/data. Reverse events following the edual data summa, naucea, pain and steesting. **Design trendscriptions Design trendscriptions**

DUIG INTERACTIONS An increase in gabapentin AUC values has been reported when administered with hydrocodone as well as with An increase in gabapentin AUC values has been reported when administered with hydrocodone as well as with DBUG INTERACTIONS An increase in galapertrin ALC values has been reported when administered with hydrocodone as well as with mappine, An antacid containing aluminum hydrocode and magnetism hydrocide reduced the bioavailability of galapertrin immediate relasses by abus approximately 20%, but by only 5% when galapertrin was taken 2 hours after antacids. It is recommended that GRAISE be taken at least 2 hours following anticeling the state there are not phermacelenets: interactions between galapertrin and the following anticeling the during there adapters in myler and costnere constraine by two. The effect of galaperior immediate relaxes of hours following anticeling the galaperint myler, and costnere constraine by two. The effect of galapering immediate relaxes on considered (400 mg three times day) had no effect on the pharmacolencies of nonethindrine 2.5 mg) or ethnic scatadio (500 mg) administered as a single table, except that the Galaperter was increased by 15%. This interactions not considered to be clinically significant. Delapertin immediate release pharmacelencies tubular accertaint by the pathway that is blacked by probeneoid.

parameters were comparised with and without protectedu, indicating that glasapetitin does not undergo rehat tabular societion by the pathwith this is blacked by protectedue. **USE IN SPECIFIC POPULATIONS Pregnance Typesary Category C Subapetitin has been shown to be fetchasic in rodents, causing delayed assistant of severa baros in the dual, writetines, forclinks, and hutlintsh. There are na declaute and well-controlled studies in program towned. This duag should be used during programs only if the patiential benefi-tion of the several baros in the dual, the tabular dual products the substantial benefits of the several baros in the local. To RNAL Several baros in the dual comment dual tabugonal patients that the several baros in the local in CR412S, Epideus are a should be patients. The name the dune by calling the to line number and the several baros is the patients. The product tabular tabular dual tabular dual tabular tabular dual tabular and tabular tabular tabular tabular tabular tabular tabular at the several baros is the several baros in the several dual tabular tabul**

DRUG ABUSE AND DEPENDENCE The abuse and dependence potential of GRALISE has not been evaluated in human studies.

OVERDOSAGE

versions are: Lethal dose of gabapentin was not identified in mice and rats receiving single oral doses as high as 8000 mg/kg. A creat active granipetrix invisition detruces in invision trans to covery stripe that dates as ling as obtain types Strips of acute transport in annuals include datase, latered transport, provide stration, Reparatively, ve exclusion. Acute and avordates of gubapetrix intredistor release in humans up to 49 grants have been reported. In these cases, databe visions, strated speech, divorciess, effetting and dardies were distored. All patters in concerned supported care. Gubapetrix on the remarked by hematalways. Although hemadaysis has not been performed in the leve versions cases reported, it must be induced by the patients' circuit state or in patient with significant renal impairment

CLINICAL PHARMACOLOGY

CURCAL PHARMACOLOGY Pharmacokinetics <u>Accounter and Expandiability</u> Galappertin is absorbed from the proximal bavel by a surtraite L-min transport system. Galappertin baveraliability is not done proportional; as the done is increased, baveraliability docurates. When GALES (1900 mg once daily) and galappertin immediate release (600 mg three inters aday were administered with high it meaks GAV actions from tail, GAUSE has a higher G_{ue} and baver AUG as stoady state compared to galappertin immediate release. Time to reach maximum plasma concentration (T_{max}) for GAUSE is 8 hours, which is about 4-6 hours longer compared to galappentin immediate release.

NONCLINICAL TOXICOLOGY

NONCLINICAL TOXECOLOFY Carcinogenesis, Mutagenesis, Impairment of Fertility Galaxpentin was given in the det to mice at 200, 600, and 2000 mg/stg/ar and to ras at 250, 1000, and 2000 mg/stg/ar g/ar years. A statistically significant increase in the noldence of puncterial action cell adortom and carcinomas was found in materials receiving the high dase theoreffect dase for the occurrence or a location may also loom g/stg/ar. Park pixona cancentrations of galaxpentin n rais receiving the high base of 2000 mg/stg/ar. Park pixona cancentrations in a streaking the high base of 2000 mg/stg/ar. Park pixona cancentrations in organized to the streaking the high base of 2000 mg/stg/ar. Park Pixona action cell carcinomas did not affect curved, did not meastable and were not loadly invesses. The relevance of this finding to carcingenic rafk in humans succious. Studies discipred to message the mechanism of galaxpentin-flucture galaxpentin did not demonstrate mutagenic or genations: potential with a difference in humon whole pulsopent has the ability in crease cell policitation in other cell bases or in after galaxpenti-multicular cells in historial difference cell policitation in other cell bases or in after galaxpentin difference in humon whole pulsopent has the ability in crease cell policitation in other cells bases to a base provide carcination in the tradition were based or in after streaking to a place of the streaking that dimensionate mutagenic or genetation; policitation as the place of the streaking to a base per defect and the adhight to recease carcination metagenic activity. It is in humon whole the laddress defects and the tensing the cell place in the streak bases to a 2000 mg/st (approximatey 11 times the maximum recommended human dase on an mg/hr basis).

Stepomed Depomed



Continued from page 36

PA did not consult with the supervising physician in the remaining 13 cases (38%). Of the 27 cases (79%) where both the PA and the supervising doctor were named in a claim or suit, the physician had examined the patient nearly 50% of the time.

Although being named as a defendant has important psychological and practical ramifications, the outcome of the case has a greater effect on a provider's future practice. Therefore, we performed a subgroup analysis based on the final disposition of the case (see Table 2).

A greater proportion of cases that were not pursued involved musculoskeletal complaints compared with cases that settled. No patient or provider characteristics, however, including intensity of supervision, were significantly associated with patient outcome or the final disposition of the case.

Of the 11 cases that settled, the median settlement for PAs was \$100,000 compared with \$200,000 for doctors. Although claims and suits against PAs usually settled for half what claims and suits against physicians did, their interquartile range of payments was substantially greater: \$12,500 to \$925,000 and \$159,000 to \$390,000, respectively.

The median cost to defend a claim or suit varied considerably depending on the final disposition. If the case was dismissed or otherwise not pursued, the median defense cost for doctors was \$28,000. If the case was settled or went to trial, the median cost was \$79,000. Defense expenses for PAs were considerably less, at \$16,000 and \$41,000, respectively.

ROLE OF DIRECT SUPERVISION

Despite having a much lower rate of malpractice litigation, we found that the distribution of claim and suit outcomes involving Colorado PAs closely approximates that of a recent nationwide study of claim and suit outcomes against physicians.⁶

Supervising doctors evaluated the patient or were consulted by the PA in two-thirds of all cases that ended in a monetary settlement or that went to trial. This high rate of direct supervision in cases the plaintiff pursued to litigation suggests that:

- PAs are involved in litigation for generally the same reasons as physicians.
- Direct supervision does not appear to protect against malpractice litigation risk.

A study of sufficient size comparing PAs who have been involved in litigation with a cohort of those who have not, based on level of supervision, may better address this issue.

Although harm is a basic component of malprac-

MedicalEconomics.com

tice claims, severity of harm did not correlate with case outcome. In fact, of the seven cases involving death, only two ended in a monetary settlement. The rest were dismissed or otherwise not pursued. Musculoskeletal complaints were the most common presenting problem and represented the greatest number of settlements. It is unclear whether this finding reflects the PAs' patient population or the high volume of musculoskeletal complaints that providers face.

Provider gender was the only other factor that appeared to be associated with increased litigation risk. Gender differences in liability risk among doctors, however, have been shown to disappear after adjusting for factors such as specialty and patient volume? Because we were unable to account for these factors in our study, we were unable to evaluate this hypothesis regarding PAs.

Finally, errors and outcomes are rarely related. Serious errors may occur without causing adverse events. Regrettable outcomes may occur despite the highest standard of care. In malpractice litigation, the quality of care delivered may not be the dominant factor that determines whether a claim prevails.

GREATEST DETERMINANT FOR RISK

For physicians, specialty is the single greatest determinant for liability risk.⁷ Because our database did not categorize all PAs by specialty, we were unable to account for this factor in our risk calculations. We were also unable to account for additional factors including patient acuity and practice volume.

Another limitation of our study was a small number of PA claims and suits, despite a relatively large number of provider-years. Although the rate of claims and suits achieves statistical significance, the subgroup analysis lacked statistical power. Additionally, our data did not attempt to address any possible difference in a practice's claims experience before and after employing a PA.

Further, our study was limited to providers insured by COPIC in Colorado. Although COPIC is the dominant professional liability insurer in the state, academic institutions were not represented in this study. Although PAs and doctors have similar policy limits, some PAs may have been subsumed under a professional corporation and may not have been identified in the study population.

Finally, the malpractice environment in a given state is largely dictated by statutes governing the practice of medicine. In this respect, Colorado has a somewhat more favorable environment for medical practice than some other states. It is unclear how our data would generalize to states with different [egal environments.

October 10, 2011 MEDICAL ECONOMICS 41

MITIGATING LITIGATION RISK

The overarching goals of healthcare risk management are to identify and reduce the risk of harm to patients and providers. Once risk is identified, a thorough evaluation must take place to develop risk reduction strategies. Identifying avoidable error is a key component of this approach.

Although PAs have a much lower rate of claims and suits than physicians, they are not immune to malpractice allegations. To protect both patients and practices, employers should be diligent in hiring and credentialing. Reducing direct doctor liability for the acts of PAs begins with the selection process. Verify education and licensure, and check for board actions in every state where the PA has practiced. Query the National Practitioner Data Bank. Perform a criminal background check and contact all references. It is also appropriate to contact past supervising physicians and coworkers, even if they are not listed on a resume.

To reduce your risk of negligent supervision, it is critical to establish protocols and practice policies. These protocols and policies should outline problems, treatments, procedures, and other matters that the PA is expected to manage independently (allowing for retrospective quality review) and those for which real-time consultation is expected. Keep records of periodic evaluations and chart reviews. Many state statutes require such supervisory steps, but it is good practice to consider them minimum standards even where they are not mandated.

A culture of collaboration is essential for effective PA/doctor partnerships and quality care. If you are a supervising physician, be available and approachable whenever PAs ask for help. Simply waiting for PAs to ask for help, though, may not always be sufficient. Invite consultation with questions such as, "Have you seen any interesting cases lately?"

Document all consultations. A simple note referencing discussion or examination by the supervising doctor is sufficient. When a PA consults a physician from outside his or her practice, the consultant's specific recommendations should be documented. Many times, consultants will not include a note in the chart unless they evaluate the patient. And because these brief interactions may be considered a form of supervision, it is essential that PAs document these consultations.

To reduce your risk of vicarious liability, PAs must keep their knowledge and skills current. Providing a continuing education allowance is a good start. Include PAs in continuing education activities alongside other practice providers. It's a good habit to schedule regular provider meetings to discuss policies and best practices. Finally, it is essential that liability insurance for

doctors and PAs address both joint and separate

42 MEDICAL ECONOMICS October 10, 2011 liability, because litigation aimed at PAs routinely involves their supervising physicians.

MORE SIMILARITIES THAN DIFFERENCES

Based on this large, structured chart review, we have found that PAs and their supervising doctors experience a low rate of malpractice litigation compared with physicians overall. Direct supervision does not appear to protect against litigation. Although we were not able to adjust for provider specialty or patient acuity, case outcomes involving PAs and doctors closely parallel outcomes involving only physicians. This finding suggests that more similarities than differences may exist between the malpractice risk of doctors and PAs.

REFERENCES

- 1. ARC-PA Accredited Programs Over Time. Available at: http://w arc-pa.org/documents/AccreditedProgamsOverTimegraphasof9.2010. pdf. May 2011.
- 2. Best Jobs in America. CNN Money. Available at: http://www.money. cnn.com/magazines/moneymag/bestjobs/2010. April 2011.
- 3. Hooker R. The globalization of the physician assistant profession. \boldsymbol{J} Physician Assist Edu. 2007;18(3):76-85 4. DeMott D. Restatement of the Law Third, Agency. American Law
- Institute; 2006. 5. Wiler J. Ginde A. State laws governing physician assistant
- practice in emergency departments (abstract). Ann Emerg Med. 2010;56(3):S93.
- Physicians Insurers Association of America. Claim Trend Analysis 2009 Edition. Rockville, MD: Physicians Insurers Association of America: 2009.
- Kane CK. Policy Research Perspectives. Medical Liability Claim Frequency: A 2007-2008 Snapshot of Physicians. American Medical Association. Available at: http://www.ama-assn.org/ama1/pub/ upload/mm/363/prp-201001-claim-freq.pdf. May 2011.



Ledges, top, is an emergency medicine physician and emergency department director of midlevel providers for TEAMHealth West at North Colorado Medical Center, Greeley. He is also the owner and manager of Physician Assistant Solutions, Victoroff, middle, is chief medical officer at Lynxcare and a risk management consultant at COPIC, where he manages the taxonomy of medical errors and researches liability implications of electronic information systems. Ginde,



bottom, is a practicing emergency physician at University of Colorado Hospital and conducts health policy research as an assistant professor of emergency medicine and epidemiology at the University of Colorado, Denver. Send your feedback to medec@advanstarcom

MedicalEconomics.com



Unfiled Notes Page 9